News

Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Data from the phase 3 PEARL study show that durvalumab does not induce statistically significant overall survival in patients with metastatic non–small cell lung cancer.

The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Phase 3 study findings have led to the FDA approval of nadofaragene firadenovec-vncg for a subgroup of patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.

Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Findings from 3 studies show that treatment with plinabulin elicits efficacy and reduces the duration of severe neutropenia in patients with non–small cell lung cancer receiving docetaxel.

Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.

A more severe symptom burden was seen in patients with isolated thrombocytopenia vs those with isolated anemia, according to findings from the phase 3 PERSIST-1 and PAC203 trials in myelofibrosis.

Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.

Laura Fernandes, PhD, Senior Statistical Director of COTA, Inc, gives 4 predictions of upcoming trends that will change how clinical trials are performed.

A safety review committee has approved the Acclaim-1 trial of ozeplasmid plus osimertinib in non–small cell lung cancer to move on to the third cohort of the study.

Treatment with olutasidenib induced durable remissions and a manageable adverse event profile in patients with relapsed/refractory acute myeloid leukemia who harbor IDH1 mutations.

A phase 2b trial of pembrolizumab plus a personalized mRNA vaccine resulted in improved recurrence-free survival in patients with resected high-risk melanoma, the first successful randomized trial of its kind.

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

Florida Cancer Specialists & Research Institute, LLC hematologists and medical oncologists were contributors to several presentations at the San Antonio Breast Cancer Symposium® this past week.

Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.

Results from MonumenTAL-1 presented during the 2022 ASH annual Meeting have led to the submission of a biologics license application for talquetamab.

KRYSTAL-1 results led the FDA to accelerate the approval of adagrasib for KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer.

The MOMENTUM trial continues to show positive results for momelotinib fro the treatment of anemic myelofibrosis.

In the real-world setting. Patients treated with the chimeric antigen receptor T-cell agent, axicabtagene ciloleucel experience similar quality-of-life outcomes to patients who were treated in clinical trials.

A phase 1/2 trial has revealed the promise of using zilovertamab plus ibrutinib for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

Results from the GeparOLA study show that neoadjuvant olaparib did not achieved better efficacy compared with carboplatin and paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Research conducted at Florida Cancer Specialists & Research Institute that is contributing to global advancements in the diagnosis and treatment of blood diseases will be presented at ASH 2022.

Charles J. Schneider, MD, FACP, discusses some of the ongoing research examining patients with anal cell carcinoma.

Ghassan K. Abou-Alfa, MD, discusses the LEAP-002 study of pembrolizumab plus lenvatinib vs lenvatinib alone in patients with unresectable hepatocellular carcinoma.

Based on the outcome of the confirmatory phase 3 OCEAN study, the FDA has requested melphalan flufenamide be withdrawn for patients with relapsed or refractory multiple myeloma.

In an interview with Targeted Oncology, Thomas Kipps, MD, PhD, explained the new treatment options and challenges being faced in the chronic lymphocytic leukemia space.

Frontline treatment with dostarlimab and chemotherapy reduced the risk of disease progression and led to better objective response rates and progression-free survival vs pembrolizumab in patients with metastatic non-squamous non–small cell lung cancer.